[go: up one dir, main page]

SV2003000836A - Profarmaco del amino acido estimulantes ref. x-14649 - Google Patents

Profarmaco del amino acido estimulantes ref. x-14649

Info

Publication number
SV2003000836A
SV2003000836A SV2002000836A SV2002000836A SV2003000836A SV 2003000836 A SV2003000836 A SV 2003000836A SV 2002000836 A SV2002000836 A SV 2002000836A SV 2002000836 A SV2002000836 A SV 2002000836A SV 2003000836 A SV2003000836 A SV 2003000836A
Authority
SV
El Salvador
Prior art keywords
profarmaco
ref
acid amino
stimulating acid
stimulating
Prior art date
Application number
SV2002000836A
Other languages
English (en)
Inventor
David Scott Coffey
James Allen Monn
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01500263A external-priority patent/EP1310480A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2003000836A publication Critical patent/SV2003000836A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)

Abstract

ESTE INVENTO SE REFIERE A PROFARMACOS DE AMINOACIDOS ESTIMULANTES SINTETICOS Y PROCESOS PARA SU PREPARACION. EL INVENTO SE REFIERE ADEMAS A METODOS PARA EL USO Y COMPUESTOS FARMACEUTICOS INCLUYENDO LOS COMPUESTOS PARA EL TRATAMIENTO DE DISFUNCIONES NEUROLOGICAS Y PSIQUIATRICAS
SV2002000836A 2001-01-11 2002-01-11 Profarmaco del amino acido estimulantes ref. x-14649 SV2003000836A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01500007 2001-01-11
EP01500206 2001-08-02
US32978601P 2001-10-16 2001-10-16
EP01500263A EP1310480A1 (en) 2001-11-07 2001-11-07 Prodrugs of excitatory amino acids

Publications (1)

Publication Number Publication Date
SV2003000836A true SV2003000836A (es) 2003-01-13

Family

ID=27440162

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002000836A SV2003000836A (es) 2001-01-11 2002-01-11 Profarmaco del amino acido estimulantes ref. x-14649

Country Status (24)

Country Link
US (1) US7256217B2 (es)
EP (1) EP1368304B1 (es)
JP (1) JP4064237B2 (es)
KR (1) KR20030090622A (es)
CN (1) CN1267407C (es)
AR (1) AR036007A1 (es)
AT (1) ATE356111T1 (es)
AU (1) AU2002228737B2 (es)
BR (1) BR0116770A (es)
CA (1) CA2433667C (es)
CZ (1) CZ303490B6 (es)
DE (1) DE60127182T2 (es)
DZ (1) DZ3461A1 (es)
ES (1) ES2282315T3 (es)
HU (1) HUP0400620A3 (es)
IL (1) IL156364A0 (es)
MX (1) MXPA03006186A (es)
NO (1) NO20033166L (es)
NZ (1) NZ526050A (es)
PE (1) PE20020829A1 (es)
PL (1) PL208413B1 (es)
SK (1) SK287934B6 (es)
SV (1) SV2003000836A (es)
WO (1) WO2002055481A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20090058A2 (hr) 2002-06-11 2009-04-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
AR079343A1 (es) * 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
HRP20160676T1 (hr) 2011-06-17 2016-07-15 Eli Lilly And Company Derivati biciklo[3.1.0]heksan-2,6-dikarboksilne kiseline kao agonisti receptora mglu2
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
TWI809089B (zh) 2018-04-17 2023-07-21 德商拜耳廠股份有限公司 用於製備具有酸不穩定的酮保護基團官能之n-醯化胺基酸酯的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
CA2195782A1 (en) 1994-08-12 1996-02-22 David Reed Helton Composition and method for treating anxiety
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
IL118727A (en) 1995-06-29 2003-01-12 Lilly Co Eli (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
DK1052246T3 (da) 1998-01-28 2003-06-16 Taisho Pharmaceutical Co Ltd Fluorholdige aminosyrederivater
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
EP1351925A1 (en) 2001-01-11 2003-10-15 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2003006489A2 (en) 2001-07-09 2003-01-23 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1463713A1 (en) 2001-11-23 2004-10-06 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2003057661A1 (en) 2001-12-21 2003-07-17 Eli Lilly And Company Prodrugs of excitatory amino acids

Also Published As

Publication number Publication date
JP2004524292A (ja) 2004-08-12
MXPA03006186A (es) 2004-02-13
EP1368304B1 (en) 2007-03-07
PE20020829A1 (es) 2002-09-21
WO2002055481A8 (en) 2003-10-02
SK8262003A3 (en) 2004-01-08
AU2002228737B2 (en) 2007-01-04
US20040121962A1 (en) 2004-06-24
ATE356111T1 (de) 2007-03-15
NO20033166D0 (no) 2003-07-10
US7256217B2 (en) 2007-08-14
JP4064237B2 (ja) 2008-03-19
HUP0400620A2 (hu) 2004-12-28
BR0116770A (pt) 2003-12-23
NO20033166L (no) 2003-09-09
EP1368304A1 (en) 2003-12-10
CA2433667C (en) 2011-06-14
CN1486298A (zh) 2004-03-31
CZ20031916A3 (en) 2004-03-17
IL156364A0 (en) 2004-01-04
HUP0400620A3 (en) 2012-09-28
NZ526050A (en) 2005-03-24
DZ3461A1 (fr) 2002-07-18
CN1267407C (zh) 2006-08-02
DE60127182T2 (de) 2007-11-22
KR20030090622A (ko) 2003-11-28
PL208413B1 (pl) 2011-04-29
SK287934B6 (sk) 2012-05-03
WO2002055481A1 (en) 2002-07-18
CZ303490B6 (cs) 2012-10-17
AR036007A1 (es) 2004-08-04
DE60127182D1 (de) 2007-04-19
CA2433667A1 (en) 2002-07-18
PL361669A1 (en) 2004-10-04
ES2282315T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
CR20110130A (es) Profármacos de aminoácidos excitadores
ECSP056019A (es) 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune
ECSP066718A (es) Derivados de pirazolo[1,5-a]pirimidin-7-il-amina para usar en el tratamiento de enfermedades dependientes de la proteina quinasa
UY28374A1 (es) Agentes terapéuticos
DZ3197A1 (fr) Acides aminés bicycliques utilises comme agents pharmaceutiques.
PA8543301A1 (es) Derivados de dihidro-benzo (b) (1,4) diazepin-2 -ona como antagonistas ii mglur2
ES2147759T3 (es) Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
UY28144A1 (es) Agentes terapéuticos
ECSP045148A (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
RU94042240A (ru) Антагонисты рецепторов возбужденных аминокислот, способ получения, промежуточные соединения, фармацевтическая композиция
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
SV2003000836A (es) Profarmaco del amino acido estimulantes ref. x-14649
MX9302327A (es) Aminoacidos ciclicos novedosos y derivados de los mismos.
ATE361749T1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
UY28839A1 (es) Agentes terapeuticos
ES2114555T3 (es) Nuevo interferon gamma humano recombinado.
ECSP045481A (es) Profármacos de aminoácidos excitadores
AR032519A1 (es) Compuestos
SE0100295D0 (sv) New compounds
WO2003006489A3 (en) Prodrugs of excitatory amino acids
EA201001895A1 (ru) Пролекарства возбуждающих аминокислот

Legal Events

Date Code Title Description
FD Lapse